- Home
- Equipment
- usa massachusetts
- immunotherapeutics
Show results for
Refine by
Immunotherapeutics Equipment Supplied In Usa Massachusetts
18 equipment items found
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to drive sufficient tumor immunogenicity, leading to poor clinical responses.1 The reason for this may be that previous vaccine models used ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Ombipepimut-S Emulsion (DSP-7888) is an investigational immunotherapeutic cancer vaccine containing 2 peptides that induce WT1-specific cytotoxic T lymphocytes (WT1-CTLs) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic malignancies and solid tumors.1,2 Researchers have identified that adding helper T-cell–inducing peptides ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso5 is a discovery-stage program leveraging a specific keystone gut bacteria (undisclosed) to potentiate the effects of Immune Checkpoint Blockade (ICB) drugs. The field of cancer therapy has been revolutionized by the use of immunotherapy. The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of these cancer immunotherapies. YSOPIA ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse. Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune ...
Manufactured by:JPT Peptide Technologies GmbH based inBerlin, GERMANY
Neo-epitopes are important targets for individualized cancer immunotherapy. Recent advancements in next generation sequencing and bioinformatic approaches to predict immunogenicity of neo-epitopes improved target selection for therapy. However, in many cases only a fraction of predicted epitopes generate a specific T-cell response. Therefore, various assay techniques such as ELISpot, ...
Manufactured by:Akoya Biosciences based inMarlborough, MASSACHUSETTS (USA)
As inventors of the PhenoImager™ technology (formerly Phenoptics™), we leverage deep expertise in multiplex imaging and cutting-edge spatial technologies to design and develop your next-generation spatial biomarker assays. Our CLIA-certified lab provides a wide range of service offerings to meet your translational and clinical research needs. Akoya’s Advanced Biopharma ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) immunoglobulin G1 (IgG1) inhibitory antibody that binds to the HGF ligand with high affinity and specificity. HGF is the natural ligand of c-Met and blocking HGF inhibits signaling through the HGF/c-Met signaling ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE416 is an orally administered rationally-defined bacterial consortium candidate being developed for the potential treatment of food allergy. VE416 consists of clonal human commensal bacterial strains selected for their ability to suppress allergic responses and manufactured under cGMP conditions. It is produced from pure, non-pathogenic clonal bacterial cell banks, which yield a standardized ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
From Ruslan Medzhitov's discovery of toll-like receptors (TLRs) as the key immune system receptors that detect infection, which spawned the field of innate immunity, to Dan Littman's efforts to identify and clone CD4 and CD8, molecules on the surface of T cells that are crucial to immune recognition and response, Vedanta's scientific co-founders have pioneered the current understanding of how the ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Adaptate Biotherapeutics is focussed on therapeutic antibodies which harness the potential of patients’ own gamma delta T cells in situ. Gamma delta T cells play a critical role in immune surveillance, recognising malignant/transformed cells through a pattern of stress markers and exerting potent and selective cytotoxicity. The recognition mechanism is not MHC restricted and not ...
Manufactured by:JPT Peptide Technologies GmbH based inBerlin, GERMANY
Clinical peptides and PepMix Peptide Pools are increasingly needed as antigen source for clinical immune monitoring, diagnostics, cell therapy and vaccine development. The diversity of applications and regulatory requirements calls for a flexible, high quality peptide partner. JPT is that partner with its outstanding know-how on peptide antigen formats, peptide specifications and formulation, ...
Manufactured by:Rational Vaccines, Inc. based inWoburn, MASSACHUSETTS (USA)
One of the most celebrated achievements of modern medicine is the eradication of the smallpox virus with the use of a live-attenuated vaccine. We are advancing the applied science of attenuating live viruses to develop an entirely new class of therapeutic and prophylactic herpes treatments, vaccines and diagnostics, through rational design. Our technology is based on the pioneering research of ...
by:Oncimmune Holdings PLC based inNottingham, UNITED KINGDOM
Oncimmune’s proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers that can help stratify patients in multiple cancer indications and with different autoimmune ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most aggressive cancers. Preliminary data have shown that ELI-002 produces a potent mKRAS-specific T-cell response, including both CD4+ and CD8+ ...